© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Author | Howard I. Scher, MD
Articles
Expanding Androgen- and Androgen Receptor Signaling–Directed Therapies for Castration-Resistant Prostate Cancer
August 15, 2014
This article reviews the most recent advances in androgen receptor-directed therapies for castration-resistant prostate cancer, and new agents under development.
Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 2
September 01, 2002
Despite the impact of prostate-specific antigen (PSA) testing on the detection and management of prostate cancer, controversy about its usefulness as a marker of disease activity continues. This review, based on a
Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 1
August 01, 2002
Despite the impact of prostate-specific antigen (PSA) testing on the detection and management of prostate cancer, controversy about its usefulness as a marker of disease activity continues. This review, based on a
Combined-Modality Therapy for Bladder Cancer
September 01, 1997
Radical cystectomy remains standard management for patients with locally advanced T2 through T4, N0, M0 transitional cell carcinoma of the urinary bladder.